RxDoctor Payments Data

John Hollowed, MD

Interventional Cardiology · Simi Valley, CANPI 1891115572

Payments from drug & device makers

$8,711in general payments, 2019–2025

Across 57 payments — averaging $152.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$5K
  • Abbott$2K
  • Boston Scientific$510
  • Shockwave Medical, Inc$442
  • Abiomed$321
  • Heartflow, Inc.$299
  • plus $322 from 6 others

What the payments were for

  • Grants$5,10059%
  • Food & beverage$3,26037%
  • Education$3504%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,711 in reported general payments places this provider in the 45th percentile of 585 interventional cardiology providers in California.

See all interventional cardiology providers in California

Medicare billing

Part B allowed, 2024
$241,891
Medicare patients
1,114
Services billed
3,029

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban87$123,003
XareltoRivaroxaban13$20,786
EntrestoSacubitril/Valsartan15$18,351
BrilintaTicagrelor22$15,682
Repatha SureclickEvolocumab15$8,145
Repatha PushtronexEvolocumab11$6,965
Metoprolol Succinate170$2,137
Rosuvastatin Calcium111$1,931
Ezetimibe82$1,434
Atorvastatin Calcium155$1,316
Nifedipine ErNifedipine19$925
ClopidogrelClopidogrel Bisulfate71$766
Amlodipine Besylate101$530
Carvedilol47$423
Losartan Potassium68$394

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$13$123,00387 claims
Johnson & JohnsonXarelto$123$20,78613 claims
AstraZenecaBrilinta$102$15,68222 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 585 interventional cardiology providers in California.

Other interventional cardiology in Simi Valley

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →